Table 1.
Studies of lenalidomide and bortezomib maintenance therapy post ASCT.
TTP indicates time to progression; MP indicates Melphalan prednisone; MPR indicates Melphalan prednisone revlimid; MPR-R indicates Melphalan prednisone revlimid-revlimid; and IR indicates incidence rate.